Pre-Clinical Efficacy and Safety Evaluation of Human Amniotic Fluid-Derived Stem Cell Injection in a Mouse Model of Urinary Incontinence
http://dx.doi.org/10.3349/ymj.2015.56.3.648 Original Article pISSN: 0513-5796, eISSN: 1976-2437 Yonsei Med J 56(3):648-657, 2015 Pre-Clinical Efficacy and Safety Evaluation of Human Amniotic Fluid-Derived Stem Cell Injection in a Mouse Model of Urinary Incontinence Jae Young Choi,1* So Young Chun,2* Bum Soo Kim,1 Hyun Tae Kim,1 Eun Sang Yoo,1 Yun-Hee Shon,2 Jeong Ok Lim,2 Seok Joong Yun,3 Phil Hyun Song,4 Sung Kwang Chung,1 James J Yoo,2,5 and Tae Gyun Kwon1,2 1Department of Urology, School of Medicine, Kyungpook National University, Daegu; 2Joint Institute for Regenerative Medicine, Kyungpook National University Hospital, Daegu; 3Department of Urology, College of Medicine, Chungbuk National University, Cheongju; 4Department of Urology, College of Medicine, Yeungnam University, Daegu, Korea; 5Wake Forest Institute for Regenerative Medicine, Wake Forest University School of Medicine, Winston-Salem, NC, USA. Received: March 31, 2014 Purpose: Stem cell-based therapies represent new promises for the treatment of Revised: August 10, 2014 urinary incontinence. This study was performed to assess optimized cell passage Accepted: August 13, 2014 number, cell dose, therapeutic efficacy, feasibility, toxicity, and cell trafficking for Corresponding author: Dr. Tae Gyun Kwon, the first step of the pre-clinical evaluation of human amniotic fluid stem cell (hAF- Department of Urology, School of Medicine, Kyungpook National University, SC) therapy in a urinary incontinence animal model. Materials and Methods: 130 Dongdeok-ro, Jung-gu, The proper cell passage number was analyzed with hAFSCs at passages 4, 6, and Daegu 700-721, Korea.
[Show full text]